|
|
| |
| Articles
by
Sadeghi B |
Total Records (
2 ) for
Sadeghi B |
|
 |
| |
|
| |
Khorram Khorshid HR
,
Sadeghi B
,
Heshmat R
,
Abdollahi M
,
Salari P
,
Farzamfar B
and
Madani SH
|
| |
Semelil is a novel herbal-based compound formulated for treatment of bed sore and diabetic foot ulcer. The objective of the present preclinical study was to assess the mutagenicity and genotoxicity of Semelil in full compliance with the standard guidelines for testing chemicals.
The potential genotoxicity of Semelil, as part of the safety evaluation process was assessed in three different in vitro and in vivo tests, including bacterial reverse mutation (Ames test), mammalian bone marrow chromosomal aberration, and rodent dominant lethal assays.
Effects of Semelil was clearly negative at different doses in the Ames test. No statistically significant differences were observed between the levels of chromosomal aberrations in bone marrow cells of mice from the experimental and control groups. The rate of post-implantation losses and thus, the number of lethal mutations in germ cells at different stages of spermatogenesis in male mice treated with a single dose of Semelil did not statistically exceed the control rate. While on the basis of these observations, Semelil can be considered genotoxically safe, further investigations using other bio-assays for mutagenicity studies are warranted.
|
|
| |
|
| |
Masoompour SM
,
Bagheri MH
,
Borhani Haghighi A
,
Novitsky YA
,
Sadeghi B
,
Gharibdoust F
,
Larijani B
and
Ranjbar Omrani G
|
| |
Diabetes foot ulcers are a major predictor of future lower-extremity amputation in patients with diabetes. The animal studies have indicated that treatment with a new herbal extract named ANGIPARS™ improves healing of chronic ulcers. The main objective of the study was to evaluate the safety and healing rates of diabetic foot ulcers in patients treated with ANGIPARS™.
Ten diabetic patients (7 males and 3 females) were eligible for enrollment in this single arm before-after clinical trial. The target wound`s greatest length and width was measured at baseline. The target wound was photographed at baseline and then every two weeks. The wound area was determined by means of planimetry.
The mean age of patients was 57± 2.3 years. The mean surface area of ulcers was 12.32±11 cm2, 9.55±9 cm2, and 6.96±6 cm2 at baseline, one month and two months of study, respectivly. Our results showed that the drug could reduce the wound size at least 50% during 8 weeks period. We found no adverse side effects in our patients.
The main conclusion of the present study was to show the efficacy and safety of ANGIPARS™ as a novel therapy in diabetic foot ulcers. |
|
|
|
|
| |
|
